Same Drug Class

Pembrolizumab vs Rituximab

Pembrolizumab vs Rituximab: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Rituximab.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days; Rituximab — 22 days.

Chemical Properties

Type: Pembrolizumab — Antibody; Rituximab — Antibody.